• Prescribing Information
  • Medical Information
  • Immunogenicity & Persistence

    TRUMENBA is the only MenB vaccine approved based on testing against 4 MenB strains representative of prevalent strains in the United States​​​​​​​1​​​​​​​

    Card CTA

    ** This is an optional area where footnotes can live.

    • Following a 3-dose schedule (0, 1-2, 6 months), 74%-94% of participants achieved a ≥4-fold immune response1,2​​​​​​​

    TRUMENBA is the only MenB vaccine that demonstrated effectiveness against 14 diverse strains with a 3-dose schedule1

    Card CTA

    ** This is an optional area where footnotes can live.

       *In a randomized, placebo-controlled, single-blinded, multicenter trial conducted in Europe, 1713 adolescents 11 through 18 years of age were assigned randomly into 5 groups to receive 2 or 3 doses of TRUMENBA: Group 1 (0, 1, and 6 months); Group 2 (0, 2, and 6 months); Group 3 (0 and 6 months); Group 4 (0 and 2 months); Group 5 (0 and 4 months).1,2

       †To achieve a 4-fold increase in immune response to TRUMENBA, a minimum hSBA (serum bactericidal activity using human complement) titer of 1:16 was measured if baseline hSBA titer was <1:4; in subjects with a baseline hSBA titer ≥1:4, an hSBA titer ≥4 times an hSBA titer ≥1:8 (1:16 for strain A22) or ≥4 times the baseline titer, whichever was higher.

       ‡Study 1 was a Phase 3, randomized, active-controlled, observer-blinded trial in adolescents 10 to 18 years of age (n=2693), and Study 2 was a Phase 3, randomized, placebo-controlled, observer-blinded trial in young adults 18 to 25 years of age (n=2471). Studies 1 and 2 were conducted in the United States, Canada, and Europe. In both studies, subjects received 3 doses of TRUMENBA on a 0, 2, and 6 months schedule.

       §To achieve a 4-fold increase in immune response to TRUMENBA, a minimum hSBA (serum bactericidal activity using human complement) titer of 1:16 was measured if baseline hSBA titer was <1:4; in subjects with a baseline titer of ≥1:4, an hSBA titer ≥4 times an hSBA titer ≥1:8 (1:16 for strain A22) or ≥4 times the baseline titer, whichever was higher.

        ||1:8 for A07, A15, A29, B03, B09, B15 and B16; 1:16 for A06, A12, A19.
    ​​​​​​​

    Card CTA

    ** This is an optional area where footnotes can live.



    TRUMENBA can help protect adolescents and young adults during their peak risk years3,4

      Card CTA

      ** This is an optional area where footnotes can live.

      Contact your Pfizer Sales Representative or call a Vaccine Specialist at
      ​​​​​​​1-844-439-2571.


      References:
      1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.
      2. Vesikari T, Ostergaard L, Diez-Domingo J, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatr Infect Dis Soc. 2015. Epub ahead of print: doi:10.1093/jpids/piv039.
      3. National Foundation for Infectious Disease. Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses. http://www.nfid.org/wp-content/uploads/2019/08/meningococcal-b-report.pdf. Accessed July 22, 2020.
      4. Patton M, Stephens D, Moore K, et al. Centers for Disease Control and Prevention. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine—Advisory Committee on Immunization Practices, 2016. MMWR. 2017;66(19):509-513.
      5. Data on file. Clinical Study Report Protocol B1071033: Table 20. Pfizer Inc. New York, NY.
      6. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated January 21, 2020. Accessed July 6, 2020.
      7. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450.
      8. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9.
      9. Ewald AJ, McKeag DB. Meningitis in the athlete. Curr Sports Med Rep. 2008;7(1):22-27.

      Efficacy & Safety

      • Safety Profile and Tolerability
      • Immunogenicity & Persistence

      Pfizer TruSupport

      • Ordering options​​​​​​​
      • Patient coverage confirmation​​​​​​
      • Essential tools
      • Resources for your practice
      Find out about TruSupport

      Why adolescents and young adults?

      Typical adolescent and young adult behaviors increase MenB risk.6-9

      Learn about MenB

      The science behind TRUMENBA

      Only TRUMENBA targets both subfamilies, A and B, of fHBP.1

      See the science

      Indication

      • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
      • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
      • Severe allergic reaction after a previous dose of Trumenba is a contraindication
      • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
      • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
      • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
      • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
      • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
      • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
      • Safety and effectiveness have not been established in pregnant women
      • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
      • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

      Please see full Prescribing Information.​​​​​​​